SCHEMBL4625909

SCHEMBL4625909

NC(=O)c1cnc2ccc(S(=O)(=O)N3CCOCC3)cc2c1Cl

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.60
PLAU P00749 1/20 0.57
LMNA P02545 3/20 0.53
GAA P10253 1/20 0.48
KMT2A Q03164 4/20 0.47
MEN1 O00255 2/20 0.47
MAPT P10636 1/20 0.47
HTT P42858 1/20 0.47
CASP3 P42574 2/20 0.47
RXFP1 Q9HBX9 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
PKM P14618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4625786 0.89 PLAU (0.54) PDE4BPLAUGAAKMT2AMEN1
SCHEMBL4656774 0.81 SLC2A1 (0.49) PDE4BPLAULMNAGAAKMT2A
SCHEMBL4627443 0.80 ALDH1A1 (0.51) PDE4BLMNAKMT2AMAPK1KDM4E
SCHEMBL4657732 0.79 PDE4B (0.49) PDE4B
SCHEMBL8305273 0.77 LMNA (0.54) PDE4BLMNAGAAKMT2AMEN1
SCHEMBL2592677 0.77 PLAU (0.54) PLAUGAAKMT2AMEN1MAPT
SCHEMBL4627084 0.75 PDE4B (0.76) PDE4B
SCHEMBL4625899 0.75 PDE4B (0.51) PDE4B
SCHEMBL2511718 0.75 PDE4B (0.48) PDE4B
SCHEMBL2479700 0.74 PDE4B (0.58) PDE4BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096884-A1 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors GLAXO GROUP LIMITED (GB) 2008-04-24 US disclosed
US-20080096884-A1 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors GLAXO GROUP LIMITED (GB) 2008-04-24 US disclosed
EP-1673086-B1 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS GLAXO GROUP LTD (GB) 2008-01-23 EP disclosed
EP-1673086-B1 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS GLAXO GROUP LTD (GB) 2008-01-23 EP disclosed
EP-1673086-A1 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS GLAXO GROUP LIMITED (GB) 2006-06-28 EP disclosed
WO-2005030212-A1 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS GLAXO GROUP LIMITED (GB) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096884-A1 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors PDE4A, PDE4B, PDE3B PDE4B 2/4885PLAU 1421/4885LMNA 3636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.